Hypoglycemic Agents

• 

  Subject Areas on Research

  • 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • A Planar Culture Model of Human Absorptive Enterocytes Reveals Metformin Increases Fatty Acid Oxidation and Export. 
  • A VGF-derived peptide attenuates development of type 2 diabetes via enhancement of islet β-cell survival and function. 
  • A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection. 
  • A futile metabolic cycle activated in adipocytes by antidiabetic agents. 
  • A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. 
  • A primer on concentrated insulins: what an internist should know. 
  • A quantitative measure of diabetes risk in community practice impacts clinical decisions: the PREVAIL initiative. 
  • A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 
  • ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. 
  • Acanthosis nigricans: a practical approach to evaluation and management. 
  • Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. 
  • Acetaminophen normalizes glucose homeostasis in mouse models for diabetes. 
  • Activated α2-macroglobulin binding to human prostate cancer cells triggers insulin-like responses. 
  • Adherence to Guidelines for Screening and Medication Use: Mortality and Onset of Major Macrovascular Complications in Elderly Persons With Diabetes Mellitus. 
  • Adherence to diabetes guidelines for screening, physical activity and medication and onset of complications and death. 
  • Adipose tissue hyaluronan production improves systemic glucose homeostasis and primes adipocytes for CL 316,243-stimulated lipolysis. 
  • Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. 
  • Alcohol-associated risks for young adults with Type 1 diabetes: a narrative review. 
  • Alterations in calcium channel currents underlie defective insulin secretion in a transgenic mouse. 
  • Alzheimer’s disease: the new promise. 
  • An outcome model approach to transporting a randomized controlled trial results to a target population. 
  • Antidiabetic drug therapy of African-American and white community-dwelling elderly over a 10-year period. 
  • Antidiabetic therapies affect risk of pancreatic cancer. 
  • Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. 
  • Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 
  • Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes. 
  • Are sulfonylureas passé? 
  • Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. 
  • Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. 
  • Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial. 
  • Association of Adverse Pregnancy Outcomes With Glyburide vs Insulin in Women With Gestational Diabetes. 
  • Association of Prenatal Care Expansion With Use of Antidiabetic Agents During Pregnancies Among Latina Emergency Medicaid Recipients With Gestational Diabetes. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS. 
  • Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease. 
  • Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. 
  • Automated Insulin Delivery Systems: Hopes and Expectations of Family Members. 
  • Automated bolus advisor control and usability study (ABACUS): does use of an insulin bolus advisor improve glycaemic control in patients failing multiple daily insulin injection (MDI) therapy? [NCT01460446]. 
  • Avoidance of weight gain is important for oral type 2 diabetes treatments in Sweden and Germany: patient preferences. 
  • BARI 2D: A Reanalysis Focusing on Cardiovascular Events. 
  • Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. 
  • Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Baseline predictors of A1C reduction in adults using sensor-augmented pump therapy or multiple daily injection therapy: the STAR 3 experience. 
  • Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences. 
  • Bed rest worsens impairments in fat and glucose metabolism in older, overweight adults. 
  • Blood Pressure Control and the Association With Diabetes Mellitus Incidence: Results From SPRINT Randomized Trial. 
  • CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. 
  • CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. 
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. 
  • Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. 
  • Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. 
  • Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. 
  • Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. 
  • Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. 
  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 
  • Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. 
  • Central and peripheral effects of insulin/IGF-1 signaling in aging and cancer: antidiabetic drugs as geroprotectors and anticarcinogens. 
  • Challenges of optimizing glycaemic control in children with Type 1 diabetes: a qualitative study of parents' experiences and views. 
  • Changes in depressive symptoms and glycemic control in diabetes mellitus. 
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. 
  • Clinical Impact of Diabetes Mellitus on Outcomes After Transcatheter Aortic Valve Replacement: Insights From the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. 
  • Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 
  • Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. 
  • Clinical associations of an updated medication effect score for measuring diabetes treatment intensity. 
  • Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. 
  • Clinical pharmacology of benoxaprofen. 
  • Clinical pharmacology of insulin confounds stroke trials. 
  • Clinical progress note: Indications for and management of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in hospitalized patients. 
  • Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. 
  • Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. 
  • Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. 
  • Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163. 
  • Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. 
  • Comparing off-pump and on-pump clinical outcomes and costs for diabetic cardiac surgery patients. 
  • Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). 
  • Comparison of Group Medical Visits Combined With Intensive Weight Management vs Group Medical Visits Alone for Glycemia in Patients With Type 2 Diabetes: A Noninferiority Randomized Clinical Trial. 
  • Comparison of an Electronic Glycemic Management System Versus Provider-Managed Subcutaneous Basal Bolus Insulin Therapy in the Hospital Setting. 
  • Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. 
  • Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). 
  • Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. 
  • Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. 
  • Controlled release of biologics for the treatment of type 2 diabetes. 
  • Controversial Issues: When the drugs don't work, can surgery provide a different outcome for diabetic adolescents? 
  • Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin. 
  • Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design. 
  • Corrections needed to 2016 ESC and AHA guidelines on heart failure. 
  • Cost-effectiveness of diabetes treatment sequences to inform step therapy policies. 
  • Cost-effectiveness of sensor-augmented pump therapy in adults with type 1 diabetes in the United States. 
  • Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. 
  • Current practices in gestational diabetes mellitus diagnosis and management in the United States: survey of maternal-fetal medicine specialists. 
  • DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. 
  • Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. 
  • Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes. 
  • Depression in persons with diabetes by age and antidiabetic treatment: a cross-sectional analysis with data from the Hordaland Health Study. 
  • Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis. 
  • Diabetes Technology and the Human Factor. 
  • Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 
  • Diabetes mellitus and insulin therapy in infective endocarditis. 
  • Diabetes on a cardiovascular ward: adherence to current recommendations. 
  • Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. 
  • Diabetic kidney disease: a report from an ADA Consensus Conference. 
  • Dietary Insulin Load and Cancer Recurrence and Survival in Patients With Stage III Colon Cancer: Findings From CALGB 89803 (Alliance). 
  • Dietary treatment of diabetes mellitus in the pre-insulin era (1914-1922). 
  • Differences in the central anorectic effects of glucagon-like peptide-1 and exendin-4 in rats. 
  • Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Direct antidiabetic effect of leptin through triglyceride depletion of tissues. 
  • Discontinuation of diabetes and lipid-lowering medications after bariatric surgery at Veterans Affairs medical centers. 
  • Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. 
  • Does medication adherence following a copayment increase differ by disease burden? 
  • Does the presence of a pharmacist in primary care clinics improve diabetes medication adherence? 
  • Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100. 
  • Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. 
  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. 
  • Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. 
  • Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial. 
  • Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial. 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. 
  • Effect of intracerebroventricular infusion of insulin on glucose-dependent insulinotropic peptide in dogs. 
  • Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. 
  • Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study. 
  • Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Effectively identifying the inpatient with hyperglycemia to increase patient care and lower costs. 
  • Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. 
  • Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial. 
  • Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes. 
  • Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Effects of intensive glucose lowering in type 2 diabetes. 
  • Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study). 
  • Effects of phentermine and phenformin on biomarkers of aging in rats. 
  • Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. 
  • Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. 
  • Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. 
  • Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial. 
  • Efficacy of metformin and fermentable fiber combination therapy in adolescents with severe obesity and insulin resistance: study protocol for a double-blind randomized controlled trial. 
  • Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. 
  • Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure. 
  • Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. 
  • Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor. 
  • Enhancement of endocrine pancreatic secretions by essential fatty acids. 
  • Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. 
  • Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. 
  • Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. 
  • Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. 
  • Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. 
  • Factors associated with non-adherence to insulin and non-insulin medications in patients with poorly controlled diabetes. 
  • Factors influencing diabetes self-management in Chinese people with type 2 diabetes. 
  • Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. 
  • Fibroblast growth factor 21 mediates specific glucagon actions. 
  • From Prescription to Transcription: Genome Sequence as Drug Target. 
  • Fusion of fibroblast growth factor 21 to a thermally responsive biopolymer forms an injectable depot with sustained anti-diabetic action. 
  • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. 
  • GLP-1 and energy balance: an integrated model of short-term and long-term control. 
  • GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs. 
  • GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. 
  • Gaps in Evidence-Based Therapy Use in Insured Patients in the United States With Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease. 
  • Gastric bypass significantly improves quality of life in morbidly obese patients with type 2 diabetes. 
  • Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • Glucagon-like peptide 1 (GLP-1). 
  • Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. 
  • Glucose control in hospitalized patients. 
  • Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. 
  • Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. 
  • Glycemic Variability and Its Impact on Quality of Life in Adults With Type 1 Diabetes. 
  • Glycemic control in patients undergoing coronary artery bypass graft surgery: Clinical features, predictors, and outcomes. 
  • Glycemic management in diabetes and the associated cardiovascular risk: are we helping or hurting our patients? 
  • Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: JACC Guideline Comparison. 
  • Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. 
  • Gut peptides in the treatment of diabetes mellitus. 
  • Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics. 
  • Heart failure event definitions in drug trials in patients with type 2 diabetes. 
  • Heterogeneity of Treatment Effects Among Patients With Type 2 Diabetes and Elevated Body Mass Index in a Study Comparing Group Medical Visits Focused on Weight Management and Medication Intensification. 
  • Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. 
  • High hemoglobin A1c associated with increased adverse limb events in peripheral arterial disease patients undergoing revascularization. 
  • High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. 
  • History of and factors associated with diabetic foot ulcers in Norway: the Nord-Trøndelag Health Study. 
  • History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. 
  • Home Use of an Artificial Beta Cell in Type 1 Diabetes. 
  • Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. 
  • Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin. 
  • Hypoglycemia Communication in Primary Care Visits for Patients with Diabetes. 
  • ISPAD Guidelines. Managing diabetes in preschool children. 
  • Impact of Chronic Sleep Disturbance for People Living With T1 Diabetes. 
  • Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. 
  • Impact of Standardized Simulated Patients on First-Year Pharmacy Students' Knowledge Retention of Insulin Injection Technique and Counseling Skills. 
  • Impact of baseline insulin regimen on glycemic response to a group medical clinic intervention. 
  • Impact of emerging health insurance arrangements on diabetes outcomes and disparities: rationale and study design. 
  • Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. 
  • Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. 
  • Impact of the Discordance Between the American College of Cardiology/American Heart Association and American Diabetes Association Recommendations on Hypertension in Patients With Diabetes Mellitus in the United States. 
  • Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. 
  • Improved glycemic control enhances the incretin effect in patients with type 2 diabetes. 
  • Improvements in health-related quality of life with liraglutide 3.0 mg compared with placebo in weight management. 
  • Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. 
  • Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. 
  • In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. 
  • In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Increased lipid accumulation and insulin resistance in transgenic mice expressing DGAT2 in glycolytic (type II) muscle. 
  • Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. 
  • Incretin mimetics as emerging treatments for type 2 diabetes. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. 
  • Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin. 
  • Insulin and longevity: antidiabetic biguanides as geroprotectors. 
  • Insulin in aging and cancer: antidiabetic drug Diabenol as geroprotector and anticarcinogen. 
  • Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. 
  • Insulin reverses the high-fat diet-induced increase in brain Aβ and improves memory in an animal model of Alzheimer disease. 
  • Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. 
  • Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. 
  • Intensive insulin therapy and mortality in critically ill patients. 
  • Intensive insulin therapy in the neurocritical care setting is associated with poor clinical outcomes. 
  • International Variation in Outcomes Among People with Cardiovascular Disease or Cardiovascular Risk Factors and Impaired Glucose Tolerance: Insights from the NAVIGATOR Trial. 
  • International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS. 
  • Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis. 
  • Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. 
  • Is iatrogenic sleep disturbance worth the effort in Type 1 diabetes? 
  • Islet α cells and glucagon--critical regulators of energy homeostasis. 
  • Isoflurane, but not halothane, induces protection of human myocardium via adenosine A1 receptors and adenosine triphosphate-sensitive potassium channels. 
  • JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk. 
  • Jump starting shared medical appointments for diabetes with weight management: Rationale and design of a randomized controlled trial. 
  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. 
  • Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Liraglutide in Weight Management. 
  • Liver dysfunction in paediatric obesity: a randomized, controlled trial of metformin. 
  • Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus. 
  • Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS. 
  • Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of Preexisting Diabetes in Pregnancy: A Review. 
  • Management of Type 1 Diabetes With a Very Low-Carbohydrate Diet. 
  • Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 
  • Measures of adherence to oral hypoglycemic agents at the primary care clinic level: the role of risk adjustment. 
  • Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial. 
  • Medication oversupply in patients with diabetes. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Metabolic syndrome: evaluation of pathological and therapeutic outcomes. 
  • Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer. 
  • Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. 
  • Metformin association with lower prostate cancer recurrence in type 2 diabetes: a systematic review and meta-analysis. 
  • Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database. 
  • Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. 
  • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. 
  • Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. 
  • Metformin is associated with improved survival in endometrial cancer. 
  • Metformin prevents tobacco carcinogen--induced lung tumorigenesis. 
  • Metformin reverses fatty liver disease in obese, leptin-deficient mice. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. 
  • Metformin use is associated with better survival of diabetic patients with pancreatic cancer. 
  • Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer. 
  • Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. 
  • Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. 
  • Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. 
  • Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. 
  • Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy. 
  • Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. 
  • N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. 
  • Neurological Prognostication After Hypoglycemic Coma: Role of Clinical and EEG Findings. 
  • Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. 
  • Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. 
  • New therapies for type 2 diabetes based on glucagon-like peptide 1. 
  • Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. 
  • Nonalcoholic fatty liver disease in women. 
  • Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. 
  • One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. 
  • One-year results from the first US-based enhanced recovery after cardiac surgery (ERAS Cardiac) program. 
  • One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. 
  • Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease. 
  • Opportunities to encourage mail order pharmacy delivery service use for diabetes prescriptions: a qualitative study. 
  • Optimizing perioperative glycemic control. 
  • Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries. 
  • Parents' experiences of managing their child's diabetes using an insulin pump: a qualitative study. 
  • Patient Preferences for Medications in Managing Type 2 Diabetes Mellitus: A Discrete Choice Experiment. 
  • Patient Self-Management of Diabetes Care in the Inpatient Setting: Pro. 
  • Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. 
  • Perceptions and experiences of using automated bolus advisors amongst people with type 1 diabetes: a longitudinal qualitative investigation. 
  • Performance of an Electronic Decision Support System as a Therapeutic Intervention During a Multicenter PICU Clinical Trial: Heart and Lung Failure-Pediatric Insulin Titration Trial (HALF-PINT). 
  • Perivascular mesenchymal cells control adipose-tissue macrophage accrual in obesity. 
  • Pharmacologic Treatment of Diabetes in Pregnancy. 
  • Pharmacological and surgical treatments for obesity. 
  • Phosphoproteomic mapping reveals distinct signaling actions and activation of muscle protein synthesis by Isthmin-1. 
  • Physical activity and NIDDM in African-Americans. The Pitt County Study. 
  • Physical activity as a determinant of fasting and 2-h post-challenge glucose: a prospective cohort analysis of the NAVIGATOR trial. 
  • Pigment epithelium-derived factor is an angiogenesis and lipid regulator that activates peroxisome proliferator-activated receptor alpha. 
  • Pimozide Alleviates Hyperglycemia in Diet-Induced Obesity by Inhibiting Skeletal Muscle Ketone Oxidation. 
  • Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. 
  • Plasma glucose response to recreational diving in novice teenage divers with insulin-requiring diabetes mellitus. 
  • Poor glycemic control is a strong predictor of postoperative morbidity and mortality in patients undergoing vascular surgery. 
  • Positive Impact of Continuous-Flow Left Ventricular Assist Device Implantation on Glycemic Control in Patients with Type 2 Diabetes Mellitus and Advanced Chronic Systolic Heart Failure. 
  • Possible differential benefits of edetate disodium in post-myocardial infarction patients with diabetes treated with different hypoglycemic strategies in the Trial to Assess Chelation Therapy (TACT). 
  • Postoperative hyperglycemia after 4- vs 8-10-mg dexamethasone for postoperative nausea and vomiting prophylaxis in patients with type II diabetes mellitus: a retrospective database analysis. 
  • Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Prescriber Continuity and Disease Control of Older Adults. 
  • Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. 
  • Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. 
  • Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. 
  • Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study. 
  • Protein kinase-zeta interacts with munc18c: role in GLUT4 trafficking. 
  • Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants. 
  • Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. 
  • ROS signaling, oxidative stress and Nrf2 in pancreatic beta-cell function. 
  • Randomized nutrition education intervention to improve carbohydrate counting in adolescents with type 1 diabetes study: is more intensive education needed? 
  • Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. 
  • Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Reduced Cost-sharing for Preventive Drugs Preferentially Benefits Low-income Patients With Diabetes in High Deductible Health Plans With Health Savings Accounts. 
  • Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Regulation of gastric emptying rate and its role in nutrient-induced GLP-1 secretion in rats after vertical sleeve gastrectomy. 
  • Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. 
  • Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). 
  • Relationship among brain and blood glucose levels and spontaneous and glucoprivic feeding. 
  • Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. 
  • Reply to Suissa and Ariel: The FULFIL Trial. 
  • Repositioning metformin for cancer prevention and treatment. 
  • Response to: 'Pharmacokinetic/pharmacodynamic properties and efficacy/safety of U-500R from randomized clinical studies'. 
  • Results of a reevaluation of cardiovascular outcomes in the RECORD trial. 
  • Revisiting NPH Insulin for Type 2 Diabetes: Is a Step Back the Path Forward? 
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. 
  • SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. 
  • Safe and Efficacious Use of Automated Bolus Advisors in Individuals Treated With Multiple Daily Insulin Injection (MDI) Therapy: Lessons Learned From the Automated Bolus Advisor Control and Usability Study (ABACUS). 
  • Safely Converting an Entire Academic Medical Center From Sliding Scale to Basal Bolus Insulin via Implementation of the eGlycemic Management System. 
  • Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 
  • Selective upregulated expression of the alpha2-macroglobulin signaling receptor in highly metastatic 1-LN prostate carcinoma cells. 
  • Self-management practices of Chinese Americans with type 2 diabetes. 
  • Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. 
  • Severe insulin resistance in a patient with type 1 diabetes and stiff-man syndrome treated with insulin lispro. 
  • Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS. 
  • Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Short-Term Adverse Outcomes Associated With Hypoglycemia in Critically Ill Children. 
  • Simplifying therapy to assure glycemic control and engagement (STAGE) in poorly-controlled diabetes: A pilot study. 
  • Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial. 
  • Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss. 
  • Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events. 
  • Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. 
  • Standardization of the single-breath diffusing capacity in a multicenter clinical trial. 
  • Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database. 
  • Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. 
  • Surgical Treatment of Diabetes: Making a Case for a Pragmatic Approach. 
  • Systemic management of diabetic retinopathy. 
  • Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model. 
  • Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. 
  • Technosphere insulin: inhaled prandial insulin. 
  • Testing a very low-carbohydrate adaption of the Diabetes Prevention Program among adults with prediabetes: study protocol for the Lifestyle Education about prediabetes (LEAP) trial. 
  • The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome. 
  • The MODY1 gene HNF-4alpha regulates selected genes involved in insulin secretion. 
  • The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. 
  • The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. 
  • The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus. 
  • The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. 
  • The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. 
  • The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. 
  • The effects of optimal perioperative glucose control on morbidly obese patients undergoing bariatric surgery. 
  • The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • The pathogenesis of insulin resistance in children: metabolic complications and the roles of diet, exercise and pharmacotherapy in the prevention of type 2 diabetes. 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. 
  • The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. 
  • The utilization of video-conference shared medical appointments in rural diabetes care. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. 
  • Time of Day When Type 1 Diabetes Patients With Eating Disorder Symptoms Most Commonly Restrict Insulin. 
  • Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease. 
  • Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. 
  • Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020. 
  • Translating the hemoglobin A1C with more easily understood feedback: a randomized controlled trial. 
  • Treatment of Type 2 diabetes mellitus in Chongqing of China: unaffordable care for the poor. 
  • Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. 
  • Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. 
  • Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 
  • Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. 
  • Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 
  • Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. 
  • Type 2 Diabetes Mellitus and Heart Failure, A Scientific Statement From the American Heart Association and Heart Failure Society of America. 
  • Type 2 diabetes, thiazolidinediones: bad to the bone? 
  • Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. 
  • Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. 
  • Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. 
  • Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. 
  • Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes. 
  • Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. 
  • Use of an automated bolus calculator reduces fear of hypoglycemia and improves confidence in dosage accuracy in patients with type 1 diabetes mellitus treated with multiple daily insulin injections. 
  • Use of an insulin bolus advisor facilitates earlier and more frequent changes in insulin therapy parameters in suboptimally controlled patients with diabetes treated with multiple daily insulin injection therapy: results of the ABACUS trial. 
  • Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. 
  • Use of automated bolus advisors may improve adherence to multiple daily insulin injection therapy. 
  • Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools. 
  • Using a low-carbohydrate diet to treat obesity and type 2 diabetes mellitus. 
  • Using genetics to enable studies on the prevention of Alzheimer's disease. 
  • Using insulin to prevent hyperglycemia in surgical patients. 
  • Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial. 
  • Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. 
  • Vanadyl sulfate inhibits NO production via threonine phosphorylation of eNOS. 
  • Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. 
  • Weight change in patients with type 2 diabetes starting basal insulin therapy: correlates and impact on outcomes. 
  • Wide clinic-level variation in adherence to oral diabetes medications in the VA. 
  • Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Freemark, Michael Scott, Robert C. Atkins, M.D. and Veronica Atkins Distinguished Professor of Pediatrics, in the School of Medicine, Pediatrics, Endocrinology
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine